Recruiting
Phase 1

REGN20934

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07594093

Conditions

Overweight or Obesity

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

REGN20934

Placebo

Study Details

Brief summary:

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.

The study is looking at:

  • What side effects REGN20934 might cause
  • How much REGN20934 is in the blood at different times
  • If the body makes antibodies to REGN20934

Conditions

Overweight or Obesity

Study ID

NCT07594093

Start date

Jun 29, 2026

Status verified date

Sep, 2026

Completion date

Feb 22, 2027

Anticipated

Primary completion date

Feb 22, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Key Inclusion Criteria:

1. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
2. Females must be of non-childbearing potential

Key Exclusion Criteria:

1. A self-reported change of body weight >5 kg within approximately 90 days of visit 2
2. History of type 1 or type 2 diabetes
3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol

Note: Other protocol defined inclusion/exclusion criteria apply

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: REGN20934

placebo comparator: Placebo

Interventions

REGN20934

Administered per the protocol

Placebo

Administered per the protocol

Primary outcome measure

  • Occurrence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 16 weeks ]
  • Severity of TEAEs [ Time Frame: Up to 16 weeks ]

Central Contacts and Locations

Central contacts

Clinical Trials Administrator

844-734-6643clinicaltrials@regeneron.com

Locations

Parexel International

Recruiting

Glendale, California, United States, 91206

More Information

Sponsor

Regeneron Pharmaceuticals

Last update posted

Sep 25, 2026

Last verified

Sep, 2026

Keywords

  • Overweight
  • Obesity or without diabetes

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-09-25. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.